Sapience Therapeutics, Inc.
Research Associate
12 days ago
Tarrytown
Demonstrated ability to collaborate. Exceptional, collaborative, dedicated team. Sapience is advancing its lead programs, ST316, a first-in-class antagonist of β-catenin, and ST101, a first-in-class antagonist of C/EBPβ, through Phase 1-2 clinical trials.